Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 133
- Registration Number
- NCT02873195
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT02862275
- Locations
- 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
- Conditions
- Interventions
- Procedure: BiopsyDrug: AtezolizumabProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: OlaparibProcedure: Positron Emission TomographyOther: Questionnaire AdministrationProcedure: X-Ray Imaging
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 81
- Registration Number
- NCT02849496
- Locations
- 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT02848651
- Locations
- 🇺🇸
Franciscan St. Francis Health; Research Services, Indianapolis, Indiana, United States
🇺🇸Virginia Piper Cancer Inst, Minneapolis, Minnesota, United States
🇺🇸Levine Cancer Institute-Carolinas Medical Center; Levine Cancer Institute-Carolinas Medical Center, Charlotte, North Carolina, United States
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT02846623
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 172
- Registration Number
- NCT02844816
- Locations
- 🇺🇸
The Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸Rush-Copley Healthcare Center, Yorkville, Illinois, United States
🇺🇸Genesys Hurley Cancer Institute, Flint, Michigan, United States
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Ovarian High Grade Serous AdenocarcinomaOvarian Seromucinous CarcinomaRecurrent Fallopian Tube Clear Cell AdenocarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Undifferentiated CarcinomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaFallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 443
- Registration Number
- NCT02839707
- Locations
- 🇺🇸
Contra Costa Regional Medical Center, Martinez, California, United States
🇺🇸Kaiser San Rafael-Gallinas, San Rafael, California, United States
🇺🇸Kaiser Permanente- Marshall Medical Offices, Redwood City, California, United States
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT02825940
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou City, China
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02814669
- Locations
- 🇺🇸
Mayo Clinic - Minnesota, Rochester, Minnesota, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, Commack, New York, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1213
- Registration Number
- NCT02807636
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Lyell McEwin Hospital, Adelaide, South Australia, Australia
🇨🇦Dr. Georges L. Dumont University Hospital Centre, Moncton, New Brunswick, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.